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Summary
Background Coronary artery bypass grafting (CABG) is the standard treatment for revascularisation in patients with 
left main coronary artery disease, but use of percutaneous coronary intervention (PCI) for this indication is increasing. 
We aimed to compare PCI and CABG for treatment of left main coronary artery disease.
Methods In this prospective, randomised, open-label, non-inferiority trial, patients with left main coronary artery 
disease were enrolled in 36 centres in northern Europe and randomised 1:1 to treatment with PCI or CABG. Eligible 
patients had stable angina pectoris, unstable angina pectoris, or non-ST-elevation myocardial infarction. Exclusion 
criteria were ST-elevation myocardial infarction within 24 h, being considered too high risk for CABG or PCI, or 
expected survival of less than 1 year. The primary endpoint was major adverse cardiac or cerebrovascular events 
(MACCE), a composite of all-cause mortality, non-procedural myocardial infarction, any repeat coronary 
revascularisation, and stroke. Non-inferiority of PCI to CABG required the lower end of the 95% CI not to exceed a 
hazard ratio (HR) of 1·35 after up to 5 years of follow-up. The intention-to-treat principle was used in the analysis if 
not speciﬁ ed otherwise. This trial is registered with ClinicalTrials.gov identiﬁ er, number NCT01496651.
Findings Between Dec 9, 2008, and Jan 21, 2015, 1201 patients were randomly assigned, 598 to PCI and 603 to CABG, 
and 592 in each group entered analysis by intention to treat. Kaplan-Meier 5 year estimates of MACCE were 29% for 
PCI (121 events) and 19% for CABG (81 events), HR 1·48 (95% CI 1·11–1·96), exceeding the limit for non-inferiority, 
and CABG was signiﬁ cantly better than PCI (p=0·0066). As-treated estimates were 28% versus 19% (1·55, 1·18–2·04, 
p=0·0015). Comparing PCI with CABG, 5 year estimates were 12% versus 9% (1·07, 0·67–1·72, p=0·77) for all-cause 
mortality, 7% versus 2% (2·88, 1·40–5·90, p=0·0040) for non-procedural myocardial infarction, 16% versus 10% 
(1·50, 1·04–2·17, p=0·032) for any revascularisation, and 5% versus 2% (2·25, 0·93–5·48, p=0·073) for stroke.
Interpretation The ﬁ ndings of this study suggest that CABG might be better than PCI for treatment of left main stem 
coronary artery disease.
Funding Biosensors, Aarhus University Hospital, and participating sites.
Introduction
Treatment of unprotected left main coronary artery 
disease with percutaneous coronary intervention (PCI) 
has increased rapidly during the past decade, following 
the favourable results of randomised trials1–4 and 
observational registry studies comparing PCI and 
coronary artery bypass grafting (CABG).5–9 At present, 
both options are used to treat left main coronary artery 
disease.10 Present guidelines recommend PCI in patients 
with left main coronary artery disease and coronary 
pathology favourable to PCI (ie, in the absence of 
complex and diﬀ use lesions).10 The guidelines are based 
primarily on the prespeciﬁ ed and powered subgroup of 
705 patients with left main coronary artery disease in the 
SYNTAX trial,11–12 which compared PCI and the 
drug-eluting Taxus stent with CABG in patients with 
three-vessel or left main coronary artery disease. The 
guidelines also refer to the ﬁ ndings of the randomised 
trials LE MANS (100 patients),1 PRECOMBAT 
(600 patients),2 and Boudriot and colleagues (201 patients)3 
trials, which included patients with left main coronary 
artery stenosis. In the randomised trials, the non-
inferiority margin was wide, because of relatively small 
patient sample sizes, and thus the trials were not powered 
to deﬁ nitively determine the best treatment for 
unprotected left main coronary artery disease.
In the NOBLE trial, we postulated that PCI with drug-
eluting stents would produce non-inferior clinical results 
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compared with CABG in revascularisation of 1200 patients 
with unprotected left main coronary artery stenosis.
Methods
Study design and participants
The Nordic-Baltic-British left main revascularisation 
study (NOBLE) is a prospective, randomised, open-label, 
non-inferiority trial, done at 36 hospitals in Latvia, 
Estonia, Lithuania, Germany, Norway, Sweden, Finland, 
the UK, and Denmark.
A local interventional cardiologist and a cardiac 
surgeon at each site prospectively assessed eligible 
patients with left main coronary artery disease. Inclusion 
criteria for study enrolment were stable angina pectoris, 
unstable angina pectoris, or acute coronary syndrome, 
together with a lesion with visually assessed stenosis 
diameter ≥50% or fractional ﬂ ow reserve ≤0·80 in the 
left main coronary artery ostium, mid-shaft, or 
bifurcation, with no more than three additional non-
complex lesions. Complex lesions were deﬁ ned as 
chronic total occlusions: bifurcation lesions requiring 
two stent techniques or lesions with calciﬁ ed or tortuous 
vessel morphology. Participant exclusion criteria were 
ST-elevation infarction within 24 h, being considered too 
high risk for CABG or PCI, or expected survival of less 
than 1 year. Patients were enrolled in the study by site 
investigators or designated staﬀ . A screening log was 
maintained in ﬁ ve centres, which recruited 506 of the 
1201 patients. All enrolled patients provided written 
informed consent. The protocol and consent forms were 
consistent with Good Clinical Practice, the Declaration 
of Helsinki, and all relevant regulations. The study was 
approved by The Central Denmark Region Committees 
on Health Research Ethics, and by national or local 
ethics committees for the individual sites as appropriate, 
and by the Danish Data Protection Agency.
Randomisation and masking
Patients for whom it was determined that equivalent 
revascularisation could be achieved with CABG or PCI 
were randomly assigned (1:1) to undergo either treatment. 
Randomisation was done by a web-based computer 
randomisation system (Trialpartner, random allocation 
sequence generated by Jakob Hjort, Institute of Clinical 
Medicine, Aarhus University, Aarhus, Denmark) in 
permutated blocks by country and centre with 
stratiﬁ cation by gender, presence of a distal left main 
coronary artery bifurcation lesion, and presence of 
diabetes. Patients were assigned to the allocated 
treatment according to randomisation by the local 
research team. However, the treating surgeon or 
cardiologist could over-rule the assignment if the patient 
was found not to be eligible for the allocated treatment or 
if the patient refused to undergo the allocated treatment. 
The study was not blinded.
Procedures
Patients were treated with the intention of achieving 
complete revascularisation of all vessels with signiﬁ cant 
lesions. In the PCI group, ostial and mid-shaft lesions 
were treated with a single stent. Distal bifurcation lesions 
could be treated with two-stent techniques, preferably the 
culotte technique. Mini crush, T-stenting, V-stenting, or a 
single-stent strategy could be used if appropriate to 
lesion morphology and the PCI’s operator experience. 
High-pressure post-dilatation after stent implantation 
was recommended for all cases. Final kissing balloon 
dilatation was encouraged after main-vessel-only stenting 
and was mandatory when a two-stent technique was used. 
Intravascular ultrasound was strongly recommended 
pre-stent and post-stent deployment. Use of drug-eluting 
stents was mandatory. In March, 2010, after treatment of 
73 patients with PCI, the Biolimus-eluting stent 
Research in context
Evidence before this study
We searched PubMed for randomised trials comparing 
percutaneous coronary intervention (PCI) with coronary artery 
bypass grafting (CABG) in the treatment of left main coronary 
artery disease with the search terms “percutaneous coronary 
intervention”, “coronary artery bypass operation”, “coronary 
artery bypass grafting”, “randomised”, or “randomized”, 
published after the introduction of drug-eluting stents between 
Jan 1, 2003, and Sept 1, 2016. We identiﬁ ed four randomised 
trials. Three trials were underpowered for clinical endpoints and 
in the SYNTAX trial, only 705 patients with left main coronary 
artery disease were included. Although, the randomised trials 
suggested that PCI was a valid alternative to CABG, we found a 
need for further documentation with a large randomised trial.
Added value of this study
Our ﬁ ndings of similar mortality but higher rates of 
myocardial infarction and repeat revascularisation in patients 
with left main coronary artery disease undergoing PCI 
compared with CABG are consistent with previous 
randomised studies. With 1201 patients included in our study 
the increased rates of major adverse cardiac or 
cerebrovascular events (MACCE) associated with PCI beyond 
1 year became signiﬁ cant, and conﬁ rm ﬁ ndings from a 
meta-analysis also showing increased MACCE after PCI at 
5 years. In contrast with the SYNTAX trial, our study 
suggested that patients with left main coronary artery disease 
had inferior outcome after PCI compared with CABG, 
irrespective of coronary lesion complexity assessed with the 
SYNTAX score.
Implications of all the available evidence
Despite similar mortality, the 5-year risk of MACCE is higher 
after PCI compared with CABG for treatment of unprotected 
left main coronary artery disease. 
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became the recom mended study stent.
Patients randomly assigned to the CABG group were 
treated according to present clinical practice. The left 
internal mammary artery was recommended for 
revascularisation of the left anterior descending coronary 
artery, whenever feasible. For other lesion locations, 
saphenous venous grafts, free arterial grafts, or the right 
internal mammary artery could be used.
After the index procedure, patients were treated 
according to local practice. Treatment included 75–150 mg 
of aspirin lifelong. In both groups, patients with acute 
coronary syndrome received 75 mg clopidogrel daily for 
12 months. All patients in the PCI groups also received 
75 mg clopidogrel daily for 12 months. Prasugrel or 
ticagrelor could be substituted for clopidogrel at the 
discretion of the PCI operator.
Diagnostic angiograms were reviewed at an 
independent core laboratory (European Cardiovascular 
Research Center [CERC], Massy, France) who were 
blinded to the assigned treatment. Diagnostic angiograms 
were scored according to the SYNTAX I score algorithm at 
both the recruitment sites and the core laboratory.13 An 
independent clinical events committee consisting of 
cardiologists and a cardiac surgeon adjudicated all 
possible events concerning cause of death, stroke, 
myocardial infarction, revascularisation, graft occlusion, 
and stent thrombosis (see appendix for list of members). 
The study was overseen by an independent Data and 
Safety Monitoring Board, which received information on 
clinical events (see appendix for list of members).
Outcomes
The primary endpoint was a composite of major adverse 
cardiac and cerebrovascular events (MACCE; death from 
any cause, non-procedural myocardial infarction,14 repeat 
revascularisation, or stroke). The main hypothesis was 
non-inferiority of PCI to CABG, assessed as the lower limit 
of the 95% CI of the hazard ratio (HR) of PCI to CABG, 
not exceeding 1·35 assessed at median 3 years follow-up.
The original primary endpoint was assessment of 
non-inferiority of PCI to CABG assessed by MACCE at 
full 2 years follow-up. However, because of low MACCE 
event rates, the primary endpoint assessment was 
January, 2015, changed to a median follow-up including 
all MACCE endpoints occurring during 5 years of follow-
up and the primary endpoint was assessed when the 
originally stipulated 275 primary endpoint events were 
reached. September, 2015, it was forecasted that the 
275 events would not be reached within full 5 years of 
follow-up, and the primary endpoint assessment was 
changed to median 3 years (appendix).
Other clinical endpoints were the individual components 
of the primary MACCE endpoint, deﬁ nite stent 
thrombosis, and symptomatic graft occlusion. Procedural 
myocardial infarctions were documented (post hoc). 
Repeat revascularisations were categorised as target lesion 
revascularisation, left main coronary artery target lesion 
revascularisation, or de-novo lesion re vascularisation. 
Functional class was reported as the maximum New York 
Heart Association (NYHA) score and chest pain was 
reported as the maximum Canadian Cardiovascular 
Society (CCS) score at up to 5 years follow-up.
Statistical analyses
The sample size calculation was based on estimated 
occurrence of the composite primary endpoint of 
MACCE after mean follow-up of 2 years. An HR of 1·36, 
comparing PCI and CABG at 1 year, was derived from the 
SYNTAX trial,11–12 and translated into 30% of PCI patients 
and 23% of CABG patients experiencing MACCE after 
2 years of follow-up. An HR of 1·35 was deﬁ ned 
accordingly as the clinically acceptable non-inferiority 
limit not to be exceeded by the one-sided 95% CI. This See Online for appendix
Figure 1: Flow chart
CABG=coronary artery bypass grafting. PCI=percutaneous coronary intervention. MI=myocardial infarction. 
*Six received CABG as index treatment and seven received no index treatment. †26 received PCI as index 
treatment and seven received no index treatment.
982 assessed for eligibility
506 enrolled695 enrolled
1201 randomised
476 excluded
239 not treatable by CABG or PCI
45 declined to participate
12 ST-elevation Ml within 24 h
94 left main coronary artery disease 
and >3 non-complex lesions
212 left main coronary artery disease 
and one or more complex lesions
19 other reasons
Systematic screening log 
(5 centres)
No systematic screening log 
(31 centres)
603 allocated to CABG
570 received CABG
33 did not receive CABG†
1 died before CABG
15 patients refused CABG
15 not eligible for CABG
2 cross over by mistake
598 allocated to PCI
585 received PCI
13 did not receive PCI*
1 died before PCI
4 patients refused PCI
4 operators refused to do PCI
4 left main coronary artery disease lesion not 
signiﬁcant
11 lost to follow-up
0 emigration
0 contact lost
11 withdrawal
592 allocated to CABG in analysis
567 received CABG
23 received PCI
6 lost to follow-up
1 emigration
2 contact lost
3 withdrawal
592 allocated to PCI in analysis
580 received PCI
7 received CABG
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corresponded to a total of 275 events, with 1200 patients, 
600 in each treatment group, required to detect non-
inferiority of PCI to CABG at 2 years follow-up. Because 
the total number of events could not be reached within 
the full 5 year follow-up period for MACCE, the primary 
endpoint was assessed at a median of 3 years of follow-up 
(see appendix for details of sample size calculation and 
changes to the primary endpoint reporting).
The intention-to-treat principle was used in the 
analysis if not speciﬁ ed otherwise. Continuous variables 
were reported as mean (SD) and compared by t test if 
they followed a Gaussian distribution. Continuous 
variables not following a Gaussian distribution were 
reported as their median value (IQR) and compared 
using the Mann-Whitney test. Binary variables were 
reported as counts and percentages, and baseline and 
in-hospital diﬀ erences between the two groups were 
assessed with the χ² or Fisher’s exact test if a cell value 
was lower than 5. Follow-up began at randomisation. In 
the analysis of individual endpoints, follow-up continued 
until the date of a clinical endpoint event, death, 
emigration, or 5 years after randomisation, whichever 
occurred ﬁ rst. All patients were followed for at least 
1 year. Clinical outcomes occurring during the 30 days 
after the index procedure and at 12 months were 
presented with risk diﬀ erences (RDs) and compared 
using the log-rank test. Extended follow-up to 5 years 
was reported using 5 year Kaplan-Meier estimates and 
HRs with 95% CIs computed on unadjusted Cox 
regression analysis. Cumulative rates of MACCE were 
stratiﬁ ed into three groups based on the core laboratory 
SYNTAX score (low: ≤22; intermediate: 23–32; and 
high: ≥33), and presented by Kaplan-Meier curves. 
A p value of less than 0·05 was considered signiﬁ cant. 
All analyses were done using Stata 12. The trial was 
registered with ISRCTN87206264 and ClinicalTrials.gov 
identiﬁ er: NCT01496651.
Role of the funding source
Aarhus University Hospital was the main sponsor of the 
trial. Biosensors provided an institutional research grant 
for the trial but had no role in the study design; in the 
collection, analysis, and interpretation of the data; in the 
writing of this report; or in the decision to submit the 
paper for publication. The corresponding author, NRH, 
and HTS had full access to all the data in the study and 
together with the writing group (appendix) had the ﬁ nal 
responsibility for the decision to submit for publication. 
We designed the study, wrote the manuscript, and vouch 
for the completeness and accuracy of data collection 
and analysis.
Results
1201 patients were enrolled from Dec 9, 2008, to Jan 21, 
2015, in 36 centres. 14 patients withdrew consent, three 
were lost to follow-up, and 1184 were included in the 
analysis (592 patients in each group; ﬁ gure 1). Patients 
were followed for at least 1 year and extended follow-up 
was available for a median of 3·1 years (IQR 2·0–5·0). 
Follow-up for the primary endpoint was continued until 
May 1, 2016, and was available for 533 (90%) and 532 (90%) 
of the study population at 2 years, 412 (69%) and 400 (67%) 
at 3 years, 308 (52%) and 293 (50%) at 4 years, and 224 
(38%) and 208 (35%) at 5 years in the PCI and CABG 
group respectively, corresponding to 69% of the total study 
follow-up completed (4094 of 5920 death-adjusted patient-
years of follow-up).
Mean ages were 66·2 years (SD 9·9) in the PCI group 
and 66·2 years (9·4) in the CABG group (p=0·91), there 
were 116 women (20%) in the PCI group and 140 (24%) 
in the CABG group (p=0·0902), and 86 patients (15%) 
had diabetes in the PCI group compared with 90 (15%) in 
the CABG group (p=0·94). The logistic EUROSCORE 
was 2 (IQR 2–4; p=0·19) in both groups and the SYNTAX 
scores were 22·4 (SD 7·8) in the PCI group and 22·3 
(7·4) (p=0·706) in the CABG group. The procedure 
indication was stable angina pectoris or silent ischaemia 
in 486 (82%) of 592 patients in the PCI group and 
491 (83%) of 591 in the CABG group (p=0·44). Distal left 
main coronary artery disease was present in 477 (81%) of 
592 patients in the PCI group and 482 (81%) of 
592 patients in the CABG group (p=0·71). Additional 
characteristics of the study population are provided in 
table 1.
PCI (n=592) CABG (n=592) p value
Age (years) 66·2 (9·9) 66·2 (9·4) 0·91
Women 116 (20%) 140 (24%) 0·09
Body-mass index (kg/m2) 27·9 (4·5) 28·1 (4·4) 0·53
Diabetes type 1 or type 2 86 (15%) 90 (15%) 0·94
Family history of ischaemic 
heart disease
321 (58%) 307 (56%) 0·45
Statin treatment 482 (82%) 464 (78%) 0·17
Hypertension 386 (65%) 389 (66%) 0·91
Active smoking 108 (19%) 127 (22%) 0·18
Previous PCI 116 (20%) 118 (20%) 0·90
Previous CABG 4 (1%) 2 (<1%) 0·41
Ejection fraction 60% (IQR 55–65) 60 (IQR 52–64) 0·27
NYHA class
I 244 (53%) 195 (43%) ··
II 135 (29·6%) 150 (33%) ··
III 57 (13%) 77 (17%) ··
IV 23 (5%) 33 (7%) 0·0120
EUROSCORE 2 (IQR 2–4) 2 (IQR 2–4) 0·18
SYNTAX score 22·5 (7·5) 22·4 (8·0) 0·74
Indication
Stable angina pectoris 486 (82%) 491 (83%) 0·66
Acute coronary syndrome 106 (18%) 100 (17%) 0·66
Lesions to be treated (n [IQR]) 2 (1–3) 2 (2–3) <0·0001
Distal LMCA lesion 477 (81%) 482 (81%) 0·77
Data are n (%), mean (SD), or median (IQR). NYHA class=New York Heart Association class. LMCA=left main coronary artery.
Table 1: Baseline characteristics by treatment group
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Among PCI-treated patients in the per-protocol analysis 
group (appendix), 312 (54%) of 580 had isolated treatment 
for left main coronary artery disease, 191 (33%) of 580 had 
one additional lesion treated, and 55 (9%) of 580 had two 
additional lesions treated. Treatment for left main 
coronary artery disease involved the bifurcation in 
508 (88%) of 579 patients in the PCI group, and two-stent 
techniques were applied in 176 (35%) of 508 patients with 
left main coronary artery bifurcation treatments. A 
ﬁ rst-generation drug-eluting stent was implanted in the 
left main coronary artery in 11% of PCI cases. The nominal 
diameter of stents in the left main coronary artery was 
4·0 mm (IQR 4·0–4·5), and was inﬂ ated to 18 atm 
(IQR 16–20). Kissing balloon inﬂ ation was done in 
277 (55%) of 508 patients, and any ostial circumﬂ ex post-
dilatation was done in 399 (79%) of 508 of left main 
coronary artery bifurcation treatments. Complete 
revascularisation was achieved in 543 (92%) of 592 patients 
treated with PCI. Intravascular ultrasound of the left main 
coronary artery was done pre-PCI in 270 (47%) and post-
PCI in 430 (74%) of 580 PCI-treated patients.
CABG was done with the on-pump technique in 
476 (84%) of 564 patients, 526 (93%) of 563 patients 
underwent arterial grafting of the left anterior descending 
artery, and 480 (86%) of 561 underwent left internal 
mammary artery plus venous grafting. Grafting with the 
right internal mammary artery was done in 
44 (8%) patients. The number of grafts per patient were 
one in 23 (4%) patients, two in 294 (52%) patients, three 
in 220 (39%) patients, four in 25 (4%) patients, and ﬁ ve 
in three (<1%) of patients (appendix).
Kaplan-Meier estimates of MACCE by intention-to-
treat after 5 years were 29% (121 events) for PCI and 
19% (81 events) for CABG (ﬁ gure 2). The HR was 1·48 
(95% CI 1·11–1·96), exceeding the limit for 
non-inferiority (1·35), and was signiﬁ cant for superiority 
of CABG compared with PCI (p=0·0066). Notably, 1 year 
rates of MACCE in the two groups were the same 
(42 [7%] vs 42 [7%]; RD 0·0, 95% CI –2·9 to 2·9, p=1·00). 
Outcome by actual treatment was 120 events (28%) in 
the PCI group versus 78 events in the CABG group (19%; 
HR 1·55, 95% CI 1·18–2·04, p=0·0015).
Table 2 shows 5 year risk estimates comparing PCI 
with CABG for all-cause mortality, non-procedural 
myocardial infarction, stroke (all were ischaemic), total 
repeat revascularisation, repeat revascularisation of the 
left main coronary artery, and de-novo lesion revasc u-
larisation during follow-up. Maximum NYHA score at up 
to 5 years follow-up was I in 57% and 54%, II in 37% and 
36%, III in 5% and 10%, and V in 1% and 0·2% in 
PCI-treated and CABG-treated patients (p=0·011), 
respectively.  Canadian Cardiovascular Society class score 
at up to 5 years follow-up was 0 in 42% and 50%, 1 in 41% 
and 35%, 2 in 14% and 13%, 3 in 3% and 2%, and 4 in 1% 
and 1% (p=0·093) in PCI and CABG, respectively.
Table 3 shows rates of outcomes, comparing the PCI 
group with the CABG group, during the 30 days following 
the index procedure for procedural myocardial infarction 
(assessable in 296 [50%] of 592 and 238 [40%] of 
592 patients), reoperation for bleeding, blood transfusion, 
surgery for a sternum infection, and surgery to address 
access site complications. The duration of the index 
treatment admission was 2 days (IQR 1–4) for PCI and 
9 days (IQR 7–13; p<0·0001) for CABG. Table 4 shows 
1 year clinical outcomes.
Comparing the PCI group with the CABG group, 5 year 
Kaplan-Meier estimates for MACCE in the SYNTAX score 
subgroups were as follows: low score (1–22) in 57 (30%) of 
Figure 2: Outcomes according to intention to treat
CABG=coronary artery bypass grafting. PCI=percutaneous coronary intervention.
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297 versus 33 (16%) of 316 (HR 1·88, 95% CI 1·23–2·89, 
p=0·0031; 613 [52%] of 1184 patients in study population); 
intermediate score (23–32) in 52 (27%) of 249 versus 
37 (22%) of 220 (1·16, 0·76–1·78, p=0·48; 469 [40%] 1184 
of study population); and high score (>32) in 12 (33%) of 
46 versus 11 (24%) of 56 (1·41, 0·62–3·20, p=0·41; 02 [9%] 
of 1184 patients in study population; ﬁ gure 3).
Discussion
The EXCEL and NOBLE studies are the largest 
international randomised studies so far, comparing PCI 
and CABG in the treatment of left main coronary artery 
disease.15 The key ﬁ ndings of the NOBLE study are that 
CABG was better than PCI for the composite endpoint of 
MACCE; all-cause mortality was similar between the two 
groups; non-procedural myocardial infarction and need 
for repeat revascularisation were increased after PCI; 
a higher rate of stroke was observed in the CABG 
group after 30 days than in the PCI group, but an 
unexpected, numerically higher rate of stroke was found 
in PCI-treated patients in 5 year estimates; maximum 
angina pectoris score was higher after PCI at up to 
5 years follow-up; the diﬀ erences in outcomes were seen 
mainly after 1 year of follow-up; and the SYNTAX score 
was not associated with MACCE after PCI.
The composite primary MACCE endpoints were 
similar in NOBLE and the SYNTAX trial except that 
NOBLE did not include peri-procedural myocardial 
infarction. We found no diﬀ erence in large 
peri-procedural myocardial infarctions between PCI and 
CABG in NOBLE, and similar to NOBLE, no diﬀ erence 
was observed at 1 year in the SYNTAX trial comparing 
the PCI group with the CABG group (MACCE: 13·7% vs 
15·8%, p=0·44).12 At 5 year follow-up in the SYNTAX 
trial, the MACCE rate was higher in the PCI group than 
in the CABG group (36·9% vs 31·0%, p=0·12).16 A meta-
analysis17 of the SYNTAX left main coronary artery 
subgroup and PRECOMBAT showed that PCI was 
associated with signiﬁ cantly higher MACCE than CABG 
after 5 years (28·3% vs 23·0%, p=0·045), as conﬁ rmed by 
the NOBLE trial.
PCI (n=592) CABG (n=592) Hazard ratio (95% CI) p value
MACCE 29% (121) 19% (81) 1·48 (1·11–1·96) 0·0066
All-cause mortality 12% (36) 9% (33) 1·07 (0·67–1·72) 0·77
Cardiac death 3% (14) 3% (15) 0·93 (0·45–1·92) 0·84
Vascular death 1% (2) <1% (1) 1·96 (0·18–21·66) 0·55
Non-procedural myocardial 
infarction
7% (29) 2% (10) 2·88 (1·40–5·90) 0·0040
Revascularisation (total) 16% (71) 10% (47) 1·50 (1·04–2·17) 0·032
Revascularisation with PCI 13% (56) 10% (45) 1·23 (0·83–1·83) 0·29
Revascularisation with CABG 4% ( 19) <1% (2) 9·40 (2·19–40·38) 0·0026
Target lesion revascularisation 12% (50) 8% (36) 1·38 (0·90–2·12) 0·14
Target LMCA revascularisation 10% (41) 9% (33) 1·23 (0·78–1·94) 0·37
De-novo lesion revascularisation* 6% (24) 3% (11) 2·34 (1·16–4·74) 0·018
Symptomatic graft occlusion or 
deﬁ nite stent thrombosis
3% (9) 4% (15) 0·59 (0·26–1·36) 0·22
Possible stent thrombosis 1% (4) 0 ·· ··
Probable stent thrombosis <1% (2) 0 ·· ··
Stroke 5% (16) 2% (7) 2·25 (0·93–5·48) 0·073
Data are Kaplan-Meier estimates % (n), unless otherwise speciﬁ ed. CABG=coronary artery bypass grafting. PCI=percutaneous coronary intervention. LMCA=left main 
coronary artery. *New lesion in non-stented segment or non-grafted vessel. 
Table 2: Kaplan-Meier 5 year estimates by intention-to-treat
PCI (n=592) CABG (n=592) Risk diﬀ erence (95% CI) p value
All-cause mortality 2 (<1%) 7 (1%) –0·8% (–1·8 to 0·1) 0·09
Cardiac death 2 (<1%) 7 (1%) –0·8% (–1·8 to 0·1) 0·09
Vascular death 0 0 0% 1·00
Procedural myocardial 
infarction*
16/296 (5%) 16/238 (7%) –1·3% (–5·4 to 2·8) 0·52
Non-procedure-related 
myocardial infarction
3 (1%) 0 0·5% (–0·06 to 1·1) 0·08
Deﬁ nite stent thrombosis or 
symptomatic graft occlusion
1 (<1%) 2 (<1%) –0·1% (–0·7 to 0·4) 0·56
Repeat revascularisation 7 (1%) 10 (2%) –0·5% (–1·8 to 0·8) 0·46
Stroke 0 4 (<1%) –0·7% (–1·3 to –0·01) 0·04
Reoperation for bleeding 1 (<1%) 23 (4%) –3·7% (–5·3 to –2·1) <0·0001
Blood transfusion 11 (2%) 150 (28%) –25·4% (–29·3 to –21·5) <0·0001
Surgery for sternum infection 0 3 (<1%) –0·5% (–1·1 to 0·07) 0·08
Surgery for access site 
complications
2 (<1%) 4 (1%) 0·3% (–1·2 to 0·5) 0·41
CT-veriﬁ ed pulmonary 
embolus
1 (<1%) 1 (<1%) 0·0% (–0·4 to 0·9) 0·99
Duration of index treatment 
admission (days)
2 (1–4) 9 (7–13) ·· <0·0001
Data are n (%), or median (IQR) unless otherwise speciﬁ ed. CABG=coronary artery bypass grafting. PCI=percutaneous 
coronary intervention. *Assessable in 534 (45%) of patients. 
Table 3: Outcomes between index procedure and 30 days of follow-up by treatment group
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Our ﬁ ndings of similar mortality but higher rates of 
myocardial infarction and repeat revascularisation in 
patients undergoing PCI than those undergoing CABG 
are consistent with previous major studies of coronary 
revascularisation in patients with left main coronary 
artery disease.1–4,16–17 The low mortality after treatment in 
both groups shows that modern revascularisation 
techniques and adjunctive therapy can lead to excellent 
survival in stable patients with left main coronary 
artery disease. Nevertheless, the increased rates of 
non-procedural myocardial infarction, repeat re-
vasculari sation, and stroke associated with PCI are 
important considerations in selecting optimum treat-
ment for individual patients.
The reason for the increase in myocardial infarctions 
during follow-up after PCI might be multifactorial because 
both target lesion-related myocardial infarctions and 
de-novo lesion myocardial infarctions were contributory. 
The main advantage of CABG might be bypassing of long-
lesion segments by grafting, which protects, to a greater 
extent, against target lesion myocardial infarctions and 
proximal de-novo lesion myocardial infarctions. Although 
the increased rate of myocardial infarctions after PCI did 
not translate into diﬀ erences in cardiac deaths, all reported 
myocardial infarctions were diagnosed during symptom-
driven hospital admissions, signalling a disadvantage for 
the patient.
Maximum angina pectoris score was higher after PCI 
than after CABG, probably contributing to the increased 
revascularisation rates in the PCI group. Increased 
revascularisation rates after PCI compared with CABG are 
consistent with previous publications on both left main 
coronary artery disease stenting1–9 and three-vessel 
coronary artery disease stenting.4,18 Although restenosis of 
drug-eluting stents has diminished over time with the 
introduction of high-pressure deployment,19 use of 
intravascular ultrasound,20 and improved stent design,21 it 
remains a weakness of PCI for treatment of left main 
coronary artery disease. This might again reﬂ ect the 
superiority of bypassing the lesion territory as well as 
segments with potentially progressive disease. Accordingly, 
we found a small diﬀ erence in target left main coronary 
artery revascularisation, but more than two-times increase 
in the need for de-novo lesion revascularisation in the PCI 
group compared with the CABG group during follow-up. 
Repeat revascularisation was done mainly with PCI, but an 
estimated 4·4% of PCI-treated patients required 
revascularisation with CABG during the 5 years of 
follow-up. Because no angiographic follow-up was done, 
rates of asymptomatic graft or stent failure are unknown.
Stroke rates were remarkably low in this study, 
especially during the ﬁ rst 30 days post-procedure. During 
follow-up, stroke rates in the surgical cohort were almost 
static, whereas in the PCI group, the very low early 
procedural stroke rate (0·0%) gradually increased over 
time to an estimated 4·9% at 5 years. These ﬁ ndings 
contrast with previous studies, which have tended to 
show a higher stroke rate for CABG, persisting at long-
term follow-up in the 5 year report of the SYNTAX left 
main coronary artery trial, whereas the diﬀ erences in 
stroke rates were limiting at longer follow-up in the other 
randomised trials. All strokes were ischaemic, with no 
clear explanation for the rate among PCI-treated patients. 
The strokes in the PCI group mainly occurred after 
1 year, coinciding with termination of dual antiplatelet 
inhibition treatment. However, the low number of 
strokes and the late separation of the stroke event curves 
do not exclude that this ﬁ nding was due to chance.
The SYNTAX score was not associated with adverse 
outcomes after PCI in contrast with the SYNTAX study.11,16 
The unexpected ﬁ nding of a substantially better outcome 
after CABG in the low SYNTAX score group could be the 
result of the fact that 87% of PCI treatments involved left 
main coronary artery bifurcation which is known to 
predict worse outcome. This might therefore represent a 
limitation of the SYNTAX score for treatment selection 
in patients with left main coronary artery disease. The 
clinical use of the SYNTAX score might be better in 
patients with multivessel disease, based on whom the 
score was developed.
30-day outcomes were noteworthy. The death rate in 
patients treated with PCI was only 0·3%, compared with 
1·2% in patients undergoing CABG. Only 1·2% of 
PCI-treated patients and 1·7% of CABG-treated patients 
required repeat revascularisation during the ﬁ rst 30 days 
post-procedure. Disadvantages of CABG manifested 
during early follow-up, with a 3·9% reoperation rate for 
bleeding, a 0·5% reoperation rate for sternum infection, 
and a 27·5% rate of blood transfusion. The median 
hospital admission period (2 days for PCI and 9 days for 
CABG) represented a signiﬁ cant diﬀ erence between the 
revascularisation modalities.
Although MACCE was exactly the same for the two 
treatment groups at 1 year, there was a signiﬁ cant 
diﬀ erence in the long-term outcomes between the PCI 
and CABG groups. This ﬁ nding suggests that selecting 
PCI (n=592) CABG 
(n=592)
Risk diﬀ erence (95% CI) p value
MACCE 42 (7%) 42 (7%) 0·0% (–2·9 to 2·9) 1·00
All-cause mortality 9 (2%) 17 (3%) –1·3% (–3·0 to 0·3) 0·11
Cardiac death 8 (1%) 13 (2%) –0·8% (–2·3 to 0·6) 0·27
Vascular death 0 1 (<1%) 0·1 (–0·1 to 0·3) 0·32
Non-procedural myocardial 
infaction
11 (2%) 8 (1%) 0·5% (–0·9 to 1·9) 0·49
Revascularisation (total) 32 (5%) 24 (4%) 1·4% (–1·1 to 3·8) 0·27
Symptomatic graft occlusion or 
deﬁ nite stent thrombosis
2 (<1)% 7 (1%) –0·8% (–1·8 to 0·1) 0·09
Stroke 2 (<1%) 6 (1%) –0·7% (–1·6 to 0·3) 0·16
Data are n (%) unless otherwise speciﬁ ed. MACCE=major adverse cardiac or cerebrovascular events. CABG=coronary 
artery bypass grafting. PCI=percutaneous coronary intervention. 
Table 4: 1-year clinical outcome by treatment group
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PCI over CABG can be justiﬁ ed in patients with reduced 
life expectancy. However, our data clearly show that the 
practice of only reporting event rates at 1 year22 in PCI 
revascularisation trials is not reliable for predicting long-
term prognosis.
In terms of surgical technique, most CABG-treated 
patients received one or more arterial grafts. Although 
high long-term patency of the internal mammary artery is 
expected,23 some vein graft degeneration can be expected 
beyond 5 years.24 We will follow all patients for MACCE 
for a full 5 years and for all-cause mortality for 10 years.
Among PCI patients, most had bifurcation left main 
coronary artery involvement, consistent with previous 
studies.11 A single-stent provisional approach was used 
for two-thirds of patients, and a third underwent dual 
stenting, chieﬂ y with the culotte technique. The optimum 
stent implantation technique in left main coronary artery 
disease is unknown,25 but adequate expansion and full 
lesion coverage are required.26 Intravascular ultrasound 
can be helpful in this regard, but less than half of 
PCI-treated patients had a pre-PCI intravascular 
ultrasound assessment and 75% had a post-PCI 
intravascular ultrasound assessment. Detailed analysis 
of the intravascular ultrasound data and stenting 
techniques could improve our understanding of 
implantation results in this trial. Most patients with left 
main coronary artery disease have artery diameters above 
4 mm (average 5·7 mm) indicating the requirement for 
post-dilatation beyond the nominal diameter.27 Bench 
testing of the 3·5 mm and 4·0 mm BioMatrix stent 
(similar platform) showed the ability to expand to 
5·9 mm.28 Larger left main arteries were possibly 
excluded by the local cardiac teams. Most patients had 
post-dilatation of the left main coronary artery, but only 
half of them had post-dilatation with balloons larger than 
4 mm. Stent underexpansion and malapposition in the 
left main coronary artery might have contributed to the 
numerically higher target left main coronary artery 
revascularisations in the PCI group.
The NOBLE results should be generalised with caution 
and also in particular the SYNTAX stratiﬁ ed results 
because they are diﬀ erent from the ﬁ ndings of previous 
studies. The change to the primary endpoint timing is a 
major limitation of our study, but was carefully considered 
by investigators and statisticians in response to the low 
event rates to avoid a vastly underpowered and probably 
inconclusive primary non-inferiority endpoint reporting. 
The reporting by Kaplan-Meier estimates could be 
aﬀ ected by a change in risk for those entering the study 
early and late, as will be determined at the full 5 year 
follow-up. However, the main 5 year Kaplan-Meier 
outcome estimates in NOBLE are in line with the results 
presented in the meta-analysis of 5 year outcome in the 
SYNTAX left main coronary artery disease and 
PRECOMBAT trials.17 Because patients in NOBLE were 
elective or stabilised, patient results might not be 
applicable in the acute setting where PCI might be 
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Figure 3: Outcomes by SYNTAX score group
CABG=coronary artery bypass grafting. PCI=percutaneous coronary intervention.
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preferred over CABG if the anatomy is suitable for PCI. 
The centres in the trials were selected according to 
interest in left main coronary artery disease and 
bifurcation treatment, and CABG might be even better 
compared to PCI when done in centres with a low volume 
of left main PCI. A small fraction of patients were treated 
with ﬁ rst-generation drug-eluting stents and the study 
stent had a strut thickness above most types of currently 
used permanent metallic stents. Nevertheless, the study 
stent is a proven device with good clinical results in 
general use,29,30 and it is therefore uncertain if the applied 
stent types aﬀ ects the general isa bility of our results.
The primary endpoint of this study clearly favoured 
surgical revascularisation. However, it was a composite 
endpoint, and the results might be interpreted in various 
ways. We saw a slight diﬀ erence in patients refusing the 
allocated treatment in favour of PCI and in some patients’ 
view, the need for surgery, the long stay in hospital, the 
risk of reoperation for bleeding and infection, and a 
longer recovery time might not be worth the lower risk of 
repeat revascularisation and myocardial infarction 
because no diﬀ erence in all-cause mortality was found.
In conclusion, the NOBLE trial showed that CABG 
might provide a better clinical outcome for treatment of 
left main coronary artery disease than PCI.
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